Skip to NavigationSkip to content


FDA approves first diagnostic tool to target triple-negative breast cancer patients

Roche’s Ventana PD-L1 Assay has become the first FDA-approved companion diagnostic for the identification of patients with triple-negative breast cancer (TNBC) who are eligible for treatment with the company’s immunotherapy combo of Tecentriq (atezolizumab) plus Abraxane chemotherapy.

The technology works via the specific staining of tumour cells and immune cells to determine which patients will benefit most from Roche’s combo treatment.

Boehringer and Ventana link up

Boehringer image

Boehringer Ingelheim has signed a deal with Roche subsidiary Ventana Medical Systems to develop companion diagnostic tests for Boehringer’s oncology programme.

Such tests have become more embedded in pharma R&D since the search for personalised treatments has grown in importance in the market for some drugs, although therapeutics and diagnostics are still not routinely alongside each other.

Roche investing $180m on US diagnostics facilities

Swiss drugmaker Roche is planning to invest $180 million and boost staff at its diagnostics subsidiary Ventana Medical Systems, as the drug industry moves closer to a personalised approach to medicine delivery.

The investment in new facilities and staff will take place at Ventana's site in Oro Valley near Tucson, Arizona, according to local news reports.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches